布罗苏马布在X链接低血症的成年人:从悉尼的一项回顾性研究的现实世界经验
Shejil Kumar1,2,3,4, Christian M Girgis2,3,4, Brian Tran2,3
1Department of Endocrinology, Royal North Shore Hospital, Sydney, NSW 2065, Australia.
JBMR plus
|December 25, 2025
概括
在X链接低血症 (XLH) 的成年人中,burosumab治疗有效地使酸盐水平正常化,并改善了硬度和身体功能. 现实世界的数据证实了布罗苏马布的存在.
科学领域:
- 内分泌学和新陈代谢学
- 遗传学和遗传性疾病
- 风湿病学和肌肉骨系统疾病
背景情况:
- 与X相关的低血症 (XLH) 是由PHEX突变引起的残疾性遗传性疾病,导致FGF-23.3升高.
- 临床试验显示,抗FGF-23抗体布罗苏马布可以改善XLH症状,但实际数据有限.
研究的目的:
- 评估burosumab在XLH成年患者的实际疗效和耐受性.
- 评估血清酸盐的变化,XLH并发症和患者报告的结果 (WOMAC分数).
主要方法:
- 对13名成年XLH患者进行了回顾性审计,这些患者接受了每4周一次的皮下布罗苏马布治疗.
- 收集了关于人口统计,XLH并发症,布罗苏马布剂量,副作用,治疗前后生物化学和WOMAC分数的数据.
主要成果:
- 所有患者在3个月内达到正常的酸盐水平;低酸盐血症消失.
- 在12个月内观察到WOMAC硬度 (-33.3%) 和身体功能 (-14.3%) 评分的显著改善.
- 布罗苏马布一般耐受性很好,并有轻微的不良反应;两名患者因高酸盐血症需要降低剂量.
结论:
- 来自两个澳大利亚中心的现实世界数据支持burosumab在XLH成年人中的疗效.
- 布罗苏马布表现出良好的耐受性,并导致改善酸盐度和自我报告的硬性和身体功能.
- 这项研究为成年XLH患者在受控试验环境之外的burosumab治疗提供了有价值的临床见解.
相关概念视频
Bioavailability Study Design: Healthy Subjects Versus Patients
248
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
248
Drug Dosing: Obese Patients
368
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
368
Drug Dosing: Geriatric Patients
395
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
395
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
382
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are...
382
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
354
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
354
Pharmacodynamics in Geriatric Patients: Effects of Age
367
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
367


